DRI Healthcare Trust’s Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat and Equity Investment in KalVista Pharmaceuticals

On November 4, 2024, DRI Healthcare Trust (“the Trust”), a global leader in providing financing to advance innovation in the life sciences industry, announced it has acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat, an investigational oral plasma kallikrein inhibitor for the treatment of Hereditary Angioedema, from KalVista Pharmaceuticals ("KalVista") for an aggregate purchase price of up to $179 million, comprised of a $100 million upfront payment, up to $57 million in a sales-based milestone payment and a one-time $22 million optional payment. Additionally, the Trust is making a $5 million investment in KalVista’s common stock in a private placement transaction. Cravath is representing DRI Healthcare Trust in connection with the transaction.

The Cravath team is led by partners Cole DuMond and Daniel J. Cerqueira and includes associates Esther Kang and Cierra Coury on M&A matters; partner David J. Kappos, of counsel Kathryn-Ann Stamm and associate Callum A.F. Sproule on intellectual property matters; partner Nicholas A. Dorsey, of counsel Virginia M. Anderson and associate Fay E. Faught on financing matters; and partner Christopher K. Fargo, of counsel Kiran Sheffrin and associate Tristan Baylor on tax matters. Vincent Joralemon also worked on intellectual property matters.